General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data

[1]  F. Liu,et al.  The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta‐analysis , 2021, Mycoses.

[2]  Zeneng Cheng,et al.  Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches , 2021, Metabolites.

[3]  Shiew-Mei Huang,et al.  Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018‐2019 Submissions to the US FDA's Office of Clinical Pharmacology , 2020, Journal of clinical pharmacology.

[4]  T. K. Ritchie,et al.  Inhibitors of Organic Anion‐Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective , 2020, Journal of clinical pharmacology.

[5]  Diane D. Wang,et al.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies , 2020, Clinical Pharmacokinetics.

[6]  R. Tyndale,et al.  Propranolol is a mechanism‐based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6‐transgenic mice: Effects on activity and drug responses , 2020, British journal of pharmacology.

[7]  L. Di,et al.  In Vitro and In Vivo Methods to Assess Pharmacokinetic Drug-Drug Interactions in Drug Discovery and Development. , 2019, Biopharmaceutics & drug disposition.

[8]  Andrew Worth,et al.  Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study , 2019, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  E. Kharasch,et al.  Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry , 2019, Drug Metabolism and Disposition.

[10]  Motohiro Kato,et al.  Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes. , 2019, Drug metabolism and pharmacokinetics.

[11]  M. Niemi,et al.  Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation , 2019, Clinical pharmacology and therapeutics.

[12]  P. German,et al.  The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection , 2018, Drug Metabolism and Disposition.

[13]  A. Mathias,et al.  Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine , 2018, Clinical pharmacology and therapeutics.

[14]  A. Mathias,et al.  Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin , 2018, Clinical pharmacology and therapeutics.

[15]  Tony K. L. Kiang.  Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir , 2018, European journal of drug metabolism and pharmacokinetics.

[16]  J. S. Min,et al.  Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling , 2017, Archives of pharmacal research.

[17]  Serge Rudaz,et al.  Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. , 2017, Journal of pharmaceutical sciences.

[18]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy , 2017, Clinical pharmacology and therapeutics.

[19]  J. Venhorst,et al.  Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  Yong-Yeon Cho,et al.  Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes , 2014, Drug design, development and therapy.

[21]  Jill Barber,et al.  Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis , 2014, Drug Metabolism and Disposition.

[22]  Supinya Dechanont,et al.  Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta‐analysis , 2014, Pharmacoepidemiology and drug safety.

[23]  A. Rettie,et al.  Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor–Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells , 2014, Drug Metabolism and Disposition.

[24]  L. Richert,et al.  Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  Á. Kittel,et al.  Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  S. Härtter,et al.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. , 2012, British journal of clinical pharmacology.

[27]  M. Nauck,et al.  Compartment‐Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo , 2012, Clinical pharmacology and therapeutics.

[28]  Diansong Zhou,et al.  A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. , 2012, British journal of clinical pharmacology.

[29]  A. Nobili,et al.  Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study , 2012, European Journal of Clinical Pharmacology.

[30]  D. Back.  New drug interactions in HIV and HCV , 2012, Retrovirology.

[31]  J. Unadkat,et al.  Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC‐MS/MS cocktail assays and RT‐PCR , 2012, Biopharmaceutics & drug disposition.

[32]  D. Whittington,et al.  Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics , 2012, Clinical pharmacology and therapeutics.

[33]  A. Collier,et al.  Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin, or Bupropion , 2012, Drug Metabolism and Disposition.

[34]  M. Ingelman-Sundberg,et al.  Genetic polymorphism and toxicology--with emphasis on cytochrome p450. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  Y. Sugiyama,et al.  Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions. , 2010, Trends in pharmacological sciences.

[36]  W. Haefeli,et al.  No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment , 2010, Antimicrobial Agents and Chemotherapy.

[37]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[38]  S. Surapaneni,et al.  In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine , 2010, Cancer Chemotherapy and Pharmacology.

[39]  C. Guillemette,et al.  The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C23-ester Glucuronide in the Liver* , 2009, The Journal of Biological Chemistry.

[40]  R. Tukey,et al.  Studies on induction of lamotrigine metabolism in transgenic UGT1 mice , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  K. Morrissey,et al.  Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction , 2008, Drug Metabolism and Disposition.

[42]  Tristan S. Maurer,et al.  A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.

[43]  D. K. Williams,et al.  Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. , 2008, Molecular nutrition & food research.

[44]  C. Falany,et al.  Positive and Negative Regulation of Human Hepatic Hydroxysteroid Sulfotransferase (SULT2A1) Gene Transcription by Rifampicin: Roles of Hepatocyte Nuclear Factor 4α and Pregnane X Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.

[45]  D. K. Williams,et al.  Effect of Goldenseal (Hydrastis canadensis) and Kava Kava (Piper methysticum) Supplementation on Digoxin Pharmacokinetics in Humans , 2007, Drug Metabolism and Disposition.

[46]  T. Moger,et al.  Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. , 2007, British journal of clinical pharmacology.

[47]  D. K. Williams,et al.  EFFECT OF MILK THISTLE (SILYBUM MARIANUM) AND BLACK COHOSH (CIMICIFUGA RACEMOSA) SUPPLEMENTATION ON DIGOXIN PHARMACOKINETICS IN HUMANS , 2006, Drug Metabolism and Disposition.

[48]  K. Yoshizato,et al.  In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[49]  K. Yoshizato,et al.  IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER , 2005, Drug Metabolism and Disposition.

[50]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[51]  Kiyomi Ito,et al.  Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.

[52]  Geraldine A Hamilton,et al.  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[53]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[54]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[55]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[56]  J. Kuper,et al.  Drug Interactions of HIV Protease Inhibitors , 1999, Drug safety.

[57]  D. Back,et al.  Metabolism of Zidovudine. , 1995, General pharmacology.

[58]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Silverman,et al.  Chapter 8 – Drug Metabolism , 2014 .

[60]  Jörg C Gerlach,et al.  HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.

[61]  O. Barberan,et al.  Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development , 2011, Drug metabolism and drug interactions.

[62]  Y. Shitara.  Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. , 2011, Drug metabolism and pharmacokinetics.

[63]  Akihiro Hisaka,et al.  General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information , 2008, Clinical pharmacokinetics.

[64]  J. Stangier.  Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.

[65]  M. Fromm,et al.  Role of P-Glycoprotein Inhibition for Drug Interactions , 2007, Clinical pharmacokinetics.

[66]  C. Falany,et al.  Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. , 2007, The Journal of pharmacology and experimental therapeutics.

[67]  S. Wrighton,et al.  An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.